Modern approach to metabolic rehabilitation of cancer patients: Biguanides (phenformin and metformin) and beyond

Future Oncology

Volumn 6, Issue 8, 2010, Pages 1313-1323

  Berstein, Lev M ^a  

^a N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

Author keywords

biguanides; cancer; diet; endocrine metabolic rehabilitation; glitazones; harmone dependent tissue; healthy lifestyle; physical activity; prevention; statins; treatment

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AFINITOR; ANTINEOPLASTIC AGENT; BIGUANIDE DERIVATIVE; EVEROLIMUS; FLUINDOSTATIN; GESTAGEN; GLIBUTIDE; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; MEVINOLIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHENFORMIN; ROSUVASTATIN; SIMVASTATIN; TAMOXIFEN; TEMSIROLIMUS; TETRAHYDROLIPSTATIN; TROGLITAZONE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REHABILITATION; CLINICAL TRIAL; ENDOMETRIUM CANCER; GLYCEMIC CONTROL; HUMAN; INSULIN RESISTANCE; LYMPHOMA; METABOLIC REHABILITATION; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SOLID TUMOR;

DIET THERAPY; EXERCISE THERAPY; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; NEOPLASMS; PHENFORMIN;

EID: 77956312069     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.87     Document Type: Review

References (93)

1. Dilman VM: Metabolic immunodepression which increases the risk of cancer. Lancet 2(8050), 1207-1209 (1977).
2. Breslow L, Agran L, Breslow DM, Morganstern M, Ellwein L: Cancer control: implications from its history. J. Natl Cancer Inst. 59(2 Suppl.), 671-686 (1977).
3. Lowe J: The Metabolic Treatment of Fibromyalgia. McDowell Publishing, Lafayette, CO, USA, 312 (2000).
4. Dilman VM: Endocrinological Oncology. Meditsina, Leningrad, Russia (1983).
5. Dilman VM, Berstein LM, Tsyrlina EV et al.: On correction of hormonal-metabolic disturbances in oncological patients. Effect of biguanides (phenformin and adebit), misclerone and diphenin. Vopr. Onkol. 21(11), 33-39 (1975).
6. Dilman VM, Ryabov SI, Tsyrlina EV et al.: Reduction of body weight, cholesterol and glucose level under influence of metformin in patients with cancer and atherosclerosis. Vopr. Onkol. 18(2), 84-86 (1972).
7. Dilman VM: Aging, Climax and Cancer. Meditsina, Leningrad, Russia (1968).
8. Dilman VM, Berstein LM, Ostroumova MN et al.: Metabolic immunodepression and metabolic immunotherapy. An attempt of improvement in immunologic response in breast cancer patients by correction of metabolic disturbances. Oncology 39, 13-19 (1982).
9. Dilman VM, Berstein LM, Yevtushenko TP et al.: Preliminary evidence on metabolic rehabilitation of cancer patients. Arch. Geschwulstf 58, 175-183 (1988).
10. Dilman V, Dean W: The Neuroendocrine Theory of Aging and Degenerative Disease. The Center for Bio-Gerontology, Pensacola, FL, USA (1992).
11. Berstein LM, Yevtushenko TP, Tsyrlina EV et al.: Comparative study of 5- and 10-years results of metabolic rehabilitation of oncological patients. In: Neuroendocrine System, Metabolism, Immunity and Cancer. Hanson KP, Dilman VM (Eds). NN Petrov Research Institute of Oncology Publ, St Petersburg, Russia, 102-112 (1992).
12. Berstein LM, Santen RJ (Eds): Innovative Endocrinology of Cancer. Landes Bioscience, Springer Science+Business Media, TX, USA (2008).
13. MacMahon B: Overview of studies on endometrial cancer and other types of cancer in humans: perspectives of an epidemiologist. Semin. Oncol. 24(1 Suppl. 1), S1-S39 (1997).
14. Berstein LM: Oncoendocrinology: Traditions, contemporary situation and perspectives. Nauka Publishers, St Petersburg, Russia (2004).
15. Barnadas A, Gil M, Sanchez-Rovira P: Neoadjuvant endocrine therapy for breast cancer: past, present and future. Anti-Cancer Drugs 19, 339-347 (2009).
16. Miller WR: Clinical, pathological, proliferative and molecular responses associated with neoadjuvant aromatase inhibitor treatment in breast cancer. J. Steroid Biochem. Mol. Biol. 118(4-5), 273-276 (2010).
17. Semiglazov VF, Semiglazov VV, Dashyan GA et al.: Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer 110(2), 244-254 (2007)
18. Bokhman JV, Chepick OF, Volkova AT, Vishnevsky AS: Can primary endometrial carcinoma stage I be cured without surgery and radiation therapy? Gynecol. Oncol. 20(2), 139-155 (1985).
19. Yamazawa K, Hirai M, Fujito A: Fertility-preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer. Hum. Reprod. 22(7), 1953-1958 (2007).
20. Blagosklonny MV: Prevention of cancer by inhibiting aging. Cancer Biol. Ther. 7, 1520-1524 (2008).
21. Berstein LM: Clinical usage of hypolipidemic and antidiabetic drugs in the prevention and treatment of cancer. Cancer Lett. 224(2), 203-212 (2005).
22. Liao JK: Clinical implications for statin pleiotropy. Curr. Opin. Lipidol. 16(6), 624-629 (2005).
23. Zhou G, Myers R, Li Y et al.: Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108(8), 1167-1174 (2001).
24. Rose DP, Vona-Davis L: Influence of obesity on breast cancer receptor status and prognosis. Expert Rev. Anticancer Ther. 9(8), 1091-1101 (2009).
25. Ruhstaller T, von Moos R, Rufibach K et al.: Breast cancer patients on endocrine therapy reveal more symptoms when self-reporting than in pivotal trials: an outcome research study. Oncology 76, 142-148 (2009).
26. Yue W, Fan P, Wang J, Li Y, Santen RJ: Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells. J. Steroid Biochem. Mol. Biol. 106, 102-110 (2007).
27. Musgrove EA, Sutherland RL: Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer 9, 631-643 (2009).
28. Saylor PJ, Smith MR: Metabolic complications of androgen deprivation therapy for prostate cancer. J. Urol. 181, 1998-2008 (2009).
29. Heideman WH, Russell NS, Gundy C, Rookus MA, Voskuil DW: The frequency, magnitude and timing of post-diagnosis body weight gain in Dutch breast cancer survivors. Eur. J. Cancer 45, 119-126 (2009).
30. McCourt CK, Mutch DG, Gibb RK et al.: Body mass index: relationship to clinical, pathologic characteristics and features of microsatellite instability in endometrial cancer. Gynecol. Oncol. 104, 535-539 (2007).
31. Golubev AG: The other side of metabolism. Biokhimiia (Moscow) 61(11), 2018-2039 (1996).
32. Unoki H, Yamagishi S: Advanced glycation end products and insulin resistance. Curr. Pharm. Des. 14(10), 987-989 (2008).
33. van Kruijsdijk RC, van der Wall E, Visseren FL: Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol. Biomarkers Prev. 18(10), 2569-2578 (2009).
34. Warburg O: On the origin of cancer cells: 30 years of research. Science 123, 309-314 (1956).
35. Shaw RJ: Glucose metabolism and cancer. Curr. Opin. Cell Biol. 18, 598-608 (2006).
36. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB: The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell. Metab. 7(1), 11-20 (2008).
37. Gogvadze V, Orrenius S, Zhivotovsky B: Mitochondria in cancer cells: what is so special about them. Trends Cell. Biol. 18, 165-173 (2008).
38. Shackelford DB, Shaw RJ: The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat. Rev. Cancer 9(8), 563-575 (2009).
39. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K: Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 69, 7507-7511 (2009).
40. Stearns V, Rae JM: Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response? Expert Rev. Mol. Med. 10, E34 (2008).
41. Aquilante CL: Pharmacogenetics of thiazolidinedione therapy. Pharmacogenomics 8(8), 917-931 (2007).
42. Reitman ML, Schadt EE: Pharmacogenetics of metformin response: a step in the path toward personalized medicine. J. Clin. Invest. 117(5), 1226-1229 (2007).
43. Berstein LM: Role of endocrine-genotoxic switchings in cancer and other human diseases: basic triad. Adv. Exp. Med. Biol. 630, 35-51 (2008).
44. Bershtein LM, Tsyrlina EV, Kovalevskii AI et al.: Endocrine-genotoxic switchings as promoter of main noninfectious diseases. Vestn. Ross. Akad. Med. Nauk. 1, 12-18 (2008) [in Russian].
45. Berstein LM: Endocrinology of the wild and mutant BRCA1 gene and types of hormonal carcinogenesis. Future Oncol. 4(1), 23-39 (2008).
46. Eliassen AH, Hankinson SE: Endogenous hormone levels and risk of breast, endometrial and ovarian cancers: prospective studies. Adv. Exp. Med. Biol. 630, 148-165 (2008).
47. Neilson HK, Friedenreich CM, Brockton NT, Millikan RC: Physical activity and postmenopausal breast cancer: proposed biologic mechanisms and areas for future research. Cancer Epidemiol. Biomarkers Prev. 18(1), 11-27 (2009).
48. Pollak M: Insulin and insulin-like growth factor signalling in neoplasia. Nat. Rev. Cancer 8, 915-928 (2008).
49. Sjóstróm L, Gummesson A, Sjóstróm CD et al.: Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol. 10, 653-662 (2009).
50. Vigersky RA, Filmore-Nassar A, Glass AR: Thyrotropin suppression by metformin. J. Clin. Endocrinol. Metab. 91, 225-227 (2006).
51. Goodwin PJ, Pritchard KI, Ennis M, Clemons M, Graham M, Fantus IG: Insulin-lowering effects of metformin in women with early breast cancer. Clin. Breast Cancer 8, 501-505 (2008).
52. Demark-Wahnefried W, Rock CL, Patrick K, Byers T: Lifestyle interventions to reduce cancer risk and improve outcomes. Am. Fam. Physician 77(11), 1573-1578 (2008).
53. Pan SY, DesMeules M: Energy intake, physical activity, energy balance, and cancer: epidemiologic evidence. Methods Mol. Biol. 472, 191-215 (2009).
54. Yeh HC, Duncan BB, Schmidt MI, Wang NY, Brancati FL: Diabetes and quitting of smoking. Ann. Intern. Med. 152, 10-17 (2010).
55. Patterson RE, Cadmus LA, Emond JA, Pierce JP: Physical activity, diet, adiposity and female breast cancer prognosis: a review of the epidemiologic literature. Maturitas 66(1), 5-15 (2010).
56. Bernstein L: Identifying population-based approaches to lower breast cancer risk. Oncogene 27(Suppl. 2), S3-S8 (2008).
57. Schernthaner G: Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors. Int. J. Clin. Pract. 63, 912-929 (2009).
58. Mann D, Reynolds K, Smith D, Muntner P: Trends in statin use and low-density lipoprotein cholesterol levels among US Adults: impact of the 2001 National Cholesterol Education Program guidelines. Ann. Pharmacother. 42(9), 1208-1215 (2008).
59. Alimova IN, Liu B, Fan Z et al.: Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 8, 909-915 (2009).
60. Anisimov VN, Berstein LM, Egormin PA et al.: Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp. Gerontol. 40, 685-693 (2005).
61. Campbell MJ, Esserman LJ, Zhou Y et al.: Breast cancer growth prevention by statins. Cancer Res. 66, 8707-8714 (2006).
62. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N: Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 67, 10804-10812 (2007).
63. Chong CR, Chabner BA: Mysterious metformin. Oncologist 14, 1178-1181 (2009).
64. Huang X, Wullschleger S, Shpiro N et al.: Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem. J. 412(2), 211-221 (2008).
65. Zhou Z, Rahme E, Pilote L: Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. Am. Heart J. 151, 273-281 (2006).
66. Kuoppala J, Lamminpää A, Pukkala E: Statins and cancer: a systematic review and meta-analysis. Eur. J. Cancer 44, 2122-2132 (2008).
67. Garwood ER, Kumar AS, Baehner FL et al.: Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res. Treat. 119, 137-144 (2010).
68. Yu HN, Noh EM, Lee YR et al.: Troglitazone enhances tamoxifen-induced growth inhibitory activity of MCF-7 cells. Biochem. Biophys. Res. Commun. 377, 242-247 (2008).
69. Ramos-Nino ME, MacLean CD, Littenberg B: Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System. BMC Med. 5, 17 (2007).
70. Rodríguez-Enríquez S, Marín-Hernández A, Gallardo-Pérez JC, Carreño-Fuentes L, Moreno-Sánchez R: Targeting of cancer energy metabolism. Mol. Nutr. Food Res. 53, 29-48 (2009).
71. Menendez JA, Vellon L, Lupu R: The antiobesity drug Orlistat induces cytotoxic effects, suppresses Her-2/neu (erbB-2) oncogene overexpression, and synergistically interacts with trastuzumab (Herceptin) in chemoresistant ovarian cancer cells. Int. J. Gynecol. Cancer 16, 219-221 (2006).
72. Chow LW, Loo WT, Toi M: Current directions for COX-2 inhibition in breast cancer. Biomed. Pharmacother. 59(Suppl. 2), S281-S284 (2005).
73. Zhang MZ, Xu J, Yao B et al.: Inhibition of 11b-hydroxysteroid dehydrogenase type II selectively blocks the tumor COX-2 pathway and suppresses colon carcinogenesis in mice and humans. J. Clin. Invest. 119(4), 876-885 (2009).
74. Gibbons JJ, Abraham RT, Yu K: Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. Semin. Oncol. 36(Suppl. 3), S3-S17 (2009).
75. Athar M, Back JH, Tang X et al.: Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol. Appl. Pharmacol. 224, 274-283 (2007).
76. Saiah E: The role of 11b-hydroxysteroid dehydrogenase in metabolic disease and therapeutic potential of 11 b-HSD1 inhibitors. Curr. Med. Chem. 15, 642-649 (2008).
77. Macciò A, Madeddu C, Mantovani G: Adipose tissue as target organ in the treatment of hormone-dependent breast cancer: new therapeutic perspectives. Obes. Rev. 10, 660-670 (2009).
78. Bozzetti F, Mori V: Nutritional support and tumour growth in humans: a narrative review of the literature. Clin. Nutr. 28, 226-230 (2009).
79. Chlebowski RT, Blackburn GL, Thomson CA et al.: Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women s Intervention Nutrition Study. J. Natl Cancer Inst. 98, 1767-1776 (2006).
80. Thomson CA, Thompson PA: Dietary patterns, risk and prognosis of breast cancer. Future Oncol. 5, 1257-1269 (2009).
81. Chan AT, Giovannucci EL: Primary prevention of colorectal cancer. Gastroenterology 138(6), 2029-2043.E10 (2010).
82. Thompson PA, Gerner EW: Current concepts in colorectal cancer prevention. Expert Rev. Gastroenterol. Hepatol. 3(4), 369-382 (2009).
83. Atiomo W, Read A, Golding M et al.: Local recruitment experience in a study comparing the effectiveness of a low glycaemic index diet with a low calorie healthy eating at achieving weight loss and reducing the risk of endometrial cancer in women with polycystic ovary syndrome. Contemp. Clin. Trials 30, 451-456 (2009).
84. Oliveria SA, Koro CE, Yood MU, Sowell M: Cancer incidence among patients treated with antidiabetic pharmacotherapy. Diabetes Metabol. Syndrome Clin. Res. Rev. 2, 47-57 (2008).
85. Garwood ER, Kumar AS, Baehner FL et al.: Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res. Treat. 119, 137-144 (2010).
86. Bowker SL, Majumdar SR, Veugelers P, Johnson JA: Increased cancer-related mortality for patients with Type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29, 254-258 (2006).
87. Currie CJ, Poole CD, Gale EA: The influence of glucose-lowering therapies on cancer risk in Type 2 diabetes. Diabetologia 52, 1766-1777 (2009)
88. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM: New users of metformin are at low risk of incident cancer: a cohort study among people with Type 2 diabetes. Diabetes Care 32, 620-625 (2009).
89. Vazquez-Martin A, Oliveras-Ferraros C, Del Barco S, Martin-Castillo B, Menendez JA: If mammalian target of metformin indirectly is mammalian target of rapamycin, then the insulin-like growth factor-1 receptor axis will audit the efficacy of metformin in cancer clinical trials. J. Clin. Oncol. 27, E207-E209 (2009).
90. Berstein LM: Metformin, insulin, breast cancer and more... Future Oncol. 5, 309-312 (2009).
91. Berstein LM, Kvatchevskaya JO, Poroshina TE et al.: Insulin resistance, its consequences for the clinical course of the disease, and possibilities of correction in endometrial cancer. J. Cancer Res. Clin. Oncol. 130, 687-693 (2004).
92. Ooi M, Kotoula V, Charalambous E: The antidiabetic biguanide metformin induces growth arrest in thyroid carcinoma cells in vitro. Presented at: Proc. 91th Annual Endocrine Soc. (USA) P2.521 (2009).
93. Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA, Bae-Jump V: Metformin is a potent inhibitor of endometrial cancer cell proliferation - implications for a novel treatment strategy. Gynecol. Oncol. 116, 92-98 (2010).